Substance / Medication

Mecamylamine

Overview

Active Ingredient
mecamylamine
RxNorm CUI
6673

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Mecamylamine treatment for alcohol dependence: a randomized controlled trial.
Petrakis Ismene L, Ralevski Elizabeth, Gueorguieva Ralitza et al. · Addiction · 2018
PMID: 28710873RCTFull text (PMC)
Reversal of mecamylamine-induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses.
Alvarez-Jimenez Ricardo, Hart Ellen P, Prins Samantha et al. · Br J Clin Pharmacol · 2018
PMID: 29319910RCTFull text (PMC)
Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder.
Chancellor Michael, Versi Eboo, Dvergsten Chris et al. · J Urol · 2015
PMID: 26073872RCT
Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia.
Roh Sungwon, Hoeppner Susanne S, Schoenfeld David et al. · Psychopharmacology (Berl) · 2014
PMID: 24114425RCTFull text (PMC)
Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.
Arnold L Eugene, Aman Michael G, Hollway Jill et al. · J Child Adolesc Psychopharmacol · 2012
PMID: 22537359RCTFull text (PMC)
Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD).
Potter Alexandra S, Ryan Katherine K, Newhouse Paul A · Hum Psychopharmacol · 2009
PMID: 19475630RCTFull text (PMC)
Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia.
Weinberger Andrea H, Sacco Kristi A, Creeden Cerissa L et al. · Schizophr Res · 2007
PMID: 17293085RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mecamylamine (substance)
SNOMED CT
372828008
UMLS CUI
C0025029
RxNorm CUI
6673

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.